nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2015 | Original Article – Cancer Research

Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis

verfasst von: Haiyan Chen, Zhujing Shen, Yeting Hu, Qian Xiao, Dikai Bei, Xiangfeng Shen, Kefeng Ding

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

As one of the most essential components of mismatch repair system, MutL homolog 1 (MLH1) plays an increasingly implicated role in initiation and promotion of colorectal carcinogenesis, with germ-line mutations in different loci. However, whether a single genetic variant in MLH1 could predict the risk of cancer was still under doubt and recent studies yielded inconsistent results. Therefore, this meta-analysis aimed at investigating the association between MLH1 single-nucleotide polymorphisms (SNPs) and colorectal cancer (CRC) risks.

Methods

A systematic literature search of PubMed, MEDLINE, Web of Science and BIOSIS databases was performed to obtain all available SNPs and studies. We focused on three SNPs (rs1800734, rs1799977 and rs63750448) with the most included studies and conducted overall and subgroup analyses after data extraction.

Results

A total of 37,347, 29,114 and 2722 patients in case and control groups were meta-analyzed in four genetic models (AA vs. BB, AB vs. BB, AA+AB vs. BB and AA vs. BB+AB) for each SNP. The overall results suggested that the mutation in rs63750447 predicted a higher CRC risk (AB vs. BB: OR 2.283, 95 % CI 1.612–3.232, P = 0.000; AA+AB vs. BB: OR 2.291, 95 % CI 1.618–3.244, P = 0.000), while rs1800734 and rs1799977 were not associated with CRC risks. Subgroup analysis according to study area, quality score and genotyping technique revealed the similar results.

Conclusions

As the first meta-analysis reporting the association between rs63750448 and CRC risk, the A allele substitution might be a risk factor for CRC. Additionally, there was no persuasive evidence showing that SNPs of rs1800734 and rs1799977 were related to CRC susceptibility.

Nur mit Berechtigung zugänglich

Abuli A, Bujanda L, Munoz J et al (2014) The MLH1 c.1852_1853delinsGC (p. K618A) variant in colorectal cancer: genetic association study in 18,723 individuals. PLoS One 9(4):e95022PubMedCentralCrossRefPubMed

Allan JM, Shorto J, Adlard J et al (2008) MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 123(10):2456–2459CrossRefPubMed

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 1088–1101

Berndt SI, Platz EA, Fallin MD et al (2007) Mismatch repair polymorphisms and the risk of colorectal cancer. Int J Cancer 120(7):1548–1554CrossRefPubMed

Campbell PT, Curtin K, Ulrich CM et al (2009) Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut 58(5):661–667PubMedCentralCrossRefPubMed

Cannavo E, Gerrits B, Marra G et al (2007) Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2. J Biol Chem 282(5):2976–2986CrossRefPubMed

Cejka P, Stojic L, Mojas N et al (2003) Methylation-induced G2/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J 22(9):2245–2254PubMedCentralCrossRefPubMed

Chao EC, Lipkin SM (2006) Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. Nucleic Acids Res 34(3):840–852PubMedCentralCrossRefPubMed

Chen H, Taylor NP, Sotamaa KM et al (2007) Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer 120(8):1684–1688CrossRefPubMed

Christensen LL, Madsen BE, Wikman FP et al (2008) The association between genetic variants in hMLH1 and hMSH2 and the development of sporadic colorectal cancer in the Danish population. BMC Med Genet 9:52PubMedCentralCrossRefPubMed

Cunningham JM, Christensen ER, Tester DJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58(15):3455–3460PubMed

De Graeff P, Crijns A, de Jong S et al (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101(1):149–159PubMedCentralCrossRefPubMed

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed

Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedCentralCrossRefPubMed

Ehsani L, Osunkoya AO (2004) Expression of MLH1 and MSH2 in urothelial carcinoma of the renal pelvis. Tumour Biol 35:8743CrossRef

Gao L-B, Pan X-M, Li L-J et al (2011) RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 125(3):827–835CrossRefPubMed

Hinrichsen I, Ernst BP, Nuber F et al (2014) Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1. Mol Cancer 13:11PubMedCentralCrossRefPubMed

Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335(7626):914PubMedCentralCrossRefPubMed

Ito E, Yanagisawa Y, Iwahashi Y et al (1999) A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1. Biochem Biophys Res Commun 256(3):488–494CrossRefPubMed

Kanao R, Hanaoka F, Masutani C (2009) A novel interaction between human DNA polymerase eta and MutLalpha. Biochem Biophys Res Commun 389(1):40–45CrossRefPubMed

Kim JC, Roh SA, Koo KH et al (2004) Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. Fam Cancer 3(2):129–137CrossRefPubMed

Koessler T, Oestergaard MZ, Song H et al (2008) Common variants in mismatch repair genes and risk of colorectal cancer. Gut 57(8):1097–1101CrossRefPubMed

Kunkel TA, Erie DA (2005) DNA mismatch repair*. Annu Rev Biochem 74:681–710CrossRefPubMed

Loeb LA, Loeb KR, Anderson JP (2003) Multiple mutations and cancer. Proc Natl Acad Sci 100(3):776–781PubMedCentralCrossRefPubMed

Mac Partlin M, Homer E, Robinson H et al (2003) Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene 22(6):819–825CrossRefPubMed

McDaid J, Loughery J, Dunne P et al (2009) MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea. Br J Cancer 101(3):441–451PubMedCentralCrossRefPubMed

Mei Q, Yan HL, Ding FX et al (2006) Single-nucleotide polymorphisms of mismatch repair genes in healthy Chinese individuals and sporadic colorectal cancer patients. Cancer Genet Cytogenet 171(1):17–23CrossRefPubMed

Muniz-Mendoza R, Ayala-Madrigal ML, Partida-Perez M et al (2012) MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer. Genet Mol Res 11(3):2315–2320CrossRefPubMed

Niv Y (2007) Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. World J Gastroenterol 13(12):1767PubMedCentralCrossRefPubMed

Ohsawa T, Sahara T, Muramatsu S et al (2009) Colorectal cancer susceptibility associated with the hMLH1 V384D variant. Mol Med Rep 2(6):887–891PubMed

Pan XM, Yang WZ, Xu GH et al (2011) The association between MLH1 -93 G>A polymorphism of DNA mismatch repair and cancer susceptibility: a meta-analysis. Mutagenesis 26(5):667–673CrossRefPubMed

Papadopoulos N, Nicolaides NC, Wei Y-F et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263(5153):1625–1629CrossRefPubMed

Picelli S, Zajac P, Zhou XL et al (2010) Common variants in human CRC genes as low-risk alleles. Eur J Cancer 46(6):1041–1048CrossRefPubMed

Picelli S, Lorenzo Bermejo J, Chang-Claude J et al (2013) Meta-analysis of mismatch repair polymorphisms within the cogent consortium for colorectal cancer susceptibility. PLoS One 8(9):e72091PubMedCentralCrossRefPubMed

Raptis S, Mrkonjic M, Green RC et al (2007) MLH1 -93G > A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst 99(6):463–474CrossRefPubMed

Rasmussen LJ, Heinen CD, Royer-Pokora B et al (2012) Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future. Hum Mutat 33(12):1617–1625CrossRefPubMed

Samowitz WS, Curtin K, Wolff RK et al (2008) The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosomes Cancer 47(10):835–844PubMedCentralCrossRefPubMed

Shastry BS (2002) SNP alleles in human disease and evolution. J Hum Genet 47(11):561–566CrossRefPubMed

Shin KH, Shin JH, Kim JH et al (2002) Mutational analysis of promoters of mismatch repair genes hMSH2 and hMLH1 in hereditary nonpolyposis colorectal cancer and early onset colorectal cancer patients: identification of three novel germ-line mutations in promoter of the hMSH2 gene. Cancer Res 62(1):38–42PubMed

Siehler SY, Schrauder M, Gerischer U et al (2009) Human MutL-complexes monitor homologous recombination independently of mismatch repair. DNA Repair 8(2):242–252PubMedCentralCrossRefPubMed

Tempfer CB, Hefler LA, Schneeberger C et al (2006) How valid is single nucleotide polymorphism (SNP) diagnosis for the individual risk assessment of breast cancer? Gynecol Endocrinol 22(3):155–159CrossRefPubMed

Thakkinstian A, McEvoy M, Minelli C et al (2005) Systematic review and meta-analysis of the association between β2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162(3):201–211CrossRefPubMed

Tulupova E, Kumar R, Hanova M et al (2005) Do polymorphisms and haplotypes of mismatch repair genes modulate risk of sporadic colorectal cancer? Mutat Res 648(1–2):40–45

van Roon EH, van Puijenbroek M, Middeldorp A et al (2010a) Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer 10(1):180PubMedCentralCrossRefPubMed

van Roon EH, van Puijenbroek M, Middeldorp A et al (2010b) Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer 10:180PubMedCentralCrossRefPubMed

Wang Y, Friedl W, Propping P et al (1998) Val384Asp in hMLH1 gene in Chinese, Japanese and German and its etiological role in colorectal cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 15(5):263–266PubMed

Wang Y, Zhou J, Li Z et al (2000) One of the etiological factors of digestive tract cancers in Chinese: the missense mutation Val384Asp in the hMLH1 gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 17(2):82–86PubMed

Wang D, Song L, Zhang X et al (2010) Etiological role of Val384Asp in hMLH1 gene in familial colorectal cancer. Acta Univ Med Nanjing 1:1–6

Wang T, Liu Y, Sima L et al (2012) Association between MLH1 -93G>a polymorphism and risk of colorectal cancer. PLoS One 7(11):e50449PubMedCentralCrossRefPubMed

Whiffin N, Broderick P, Lubbe SJ et al (2011) MLH1-93G>A is a risk factor for MSI colorectal cancer. Carcinogenesis 32(8):1157–1161CrossRefPubMed

Zhang XM, Li JT, Zhu M et al (2004) Study on the relationship between genetic polymorphism Val384Asp in hMLH1 gene and the risk of four different carcinomas. Zhonghua Liu Xing Bing Xue Za Zhi 25(11):978–981PubMed

Zhang L, Cao J, Shen W et al (2011) Correlation between hMLH1-93G/A Gene Polymorphism and Colorectal Cancer. Chin J Gastroenterol 16(4):214–217

Zhao N, Zhu F, Yuan F et al (2008) The interplay between hMLH1 and hMRE11: role in MMR and the effect of hMLH1 mutations. Biochem Biophys Res Commun 370(2):338–343PubMedCentralCrossRefPubMed

Titel: Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis
verfasst von: Haiyan Chen
Zhujing Shen
Yeting Hu
Qian Xiao
Dikai Bei
Xiangfeng Shen
Kefeng Ding
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-1976-4

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis